EUVIMEDEUVIMED entdecken
Open Access

The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients

Matthew Torre, Patrick Y Wen, J Bryan Iorgulescu iD

Neuro-Oncology Practice · 24.03.2023 · 10 (2) · 126-131

DOI: 10.1093/nop/npac070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 10.09.2022. Verfasst von Matthew Torre und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital and Harvard Medical School; Boston, MA, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma patients with hypermethylation of the O6-methylguanine-methyltransferase (MGMT) gene promoter have significantly improved survival when treated with temozolomide compared to patients with unmethylation of the MGMT promoter. However, the prognostic and predictive significance of partial MGMT promoter methylation is unclear.

Methods

The National Cancer Database was queried for patients newly diagnosed in 2018 with histopathologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma. The overall survival (OS) associated with MGMT promoter methylation status was assessed using multivariable Cox regression with Bonferroni correction for multiple testing (P < .008 was significant).

Results

Three thousand eight hundred twenty-five newly diagnosed IDH-wildtype glioblastoma patients were identified. The MGMT promoter was unmethylated in 58.7% (n = 2245), partially methylated in 4.8% (n = 183), hypermethylated in 3.5% (n = 133), and methylated not otherwise specified (NOS; likely consisting predominantly of hypermethylated cases) in 33.0% (n = 1264) of cases. Among patients that received first-line single-agent chemotherapy (ie likely temozolomide), compared to partial methylation (referent), MGMT promoter unmethylation was associated with worse OS (hazard ratio [HR] 1.94; 95% confidence interval [95 CI]: 1.54–2.44; P < .001) in multivariable Cox regression adjusted for major prognostic confounders. In contrast, a significant OS difference was not observed between partially methylated promoters and either hypermethylated (HR 1.02; 95 CI: 0.72–1.46; P = .90) or methylated NOS (HR 0.99; 95 CI: 0.78–1.26; P = .93) promoters. Among IDH-wildtype glioblastoma patients who did not receive first-line chemotherapy, MGMT promoter methylation status was not associated with significant differences in OS (P = 0.39–0.83).

Conclusions

Compared to MGMT promoter unmethylation, partial methylation was predictive of improved OS among IDH-wildtype glioblastoma patients treated with first-line single-agent chemotherapy—supporting the use of temozolomide therapy in these patients.

Schlagwörter

Stichwörter der Autor:innen

O6-methylguanine-DNA methyltransferase (MGMT) promoterepidemiologyglioblastomamethylation

Autor:innen und Institutionen

  • Department of Pathology, Brigham and Women's Hospital and Harvard Medical School; Boston, MA, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School; Boston, MA, USA.
  • Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: J Bryan Iorgulescu

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • National Institutes of Health
  • Conquer Cancer Foundation
  • Sontag Foundation

Zitieren

APA

Torre, M., Wen, P. Y., & Iorgulescu, J. B. (2023). The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients. Neuro-Oncology Practice, 10(2), 126-131. https://doi.org/10.1093/nop/npac070

Vancouver

Torre M, Wen PY, Iorgulescu JB. The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients. Neuro-Oncology Practice. 2023;10(2):126-131. doi:10.1093/nop/npac070

BibTeX
@article{Torre2023,
  author = {Torre, Matthew and Wen, Patrick Y and Iorgulescu, J Bryan},
  title = {The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients},
  journal = {Neuro-Oncology Practice},
  year = {2023},
  volume = {10},
  number = {2},
  pages = {126--131},
  doi = {10.1093/nop/npac070}
}
Kostenlos starten →